313
Participants
Start Date
May 7, 2018
Primary Completion Date
April 16, 2022
Study Completion Date
April 16, 2022
1.0mg Varenicline b.i.d.
Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
0.5mg Varenicline b.i.d.
Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
0.0mg placebo Varenicline b.i.d.
Product that looks like active varenicline, but contains no active ingredient
Arizona State University, Phoenix
Los Angeles Clinical Trials, Burbank
Collaborators (2)
National Institute on Drug Abuse (NIDA)
NIH
Los Angeles Clinical Trials
UNKNOWN
University of Nevada, Reno
OTHER
Pfizer
INDUSTRY
Arizona State University
OTHER